SV Life Sciences announced the appointment of three new venture partners strengthening the firm’s expertise in biotechnology and health care services.
The new SVLS venture partners include: Sarah Bodary, Ph.D., focused in biotechnology and based in the San Francisco office. Gary Velasquez, focused in health care services and based in the San Francisco office; and Kevin Barrett, focused in health care services and based in the Boston office. Sarah Bodary joins in the company with over 20 years experience in research, drug development and licensing in the biotech industry.
As a biologist at Genentech, she led teams that developed peptide and small molecule antagonists of cell adhesion from discovery through clinical trials. She was also a member of the development and launch teams for the Raptiva(R) antibody.
Most recently Dr. Bodary was responsible for licensing at Schering-Plough Biopharma, the biologics subsidiary of Schering-Plough. Gary Velasquez recently rejoined SVLS as a venture partner with more than 25 years of experience in healthcare services, having previously left that role in 2004 to join Synarc as President and Chief Executive Officer. Synarc was successfully exited by SVLSFIII in 2008. Mr. Velasquez currently serves on the board of directors of SVLS portfolio company Socios Mayores. Kevin Barrett has had a long career within the health care services field and was previously a founding partner of Commonwealth Health Partners, a specialized consulting and advisory firm focusing on the healthcare services and healthcare information technology markets.
Prior to that, Mr. Barrett served as executive vice president and chief development officer of PolyMedica.-Business Wire
